Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTLA Intellia Therapeutics Inc

盘后交易 03-25 18:01:29 EDT

13.26

+0.45

+3.51%

盘后13.37

+0.11+0.83%

17:48 EDT

最高13.67	最低13.03	成交量300.55万
今开13.11	昨收12.81	日振幅4.98%
总市值15.66亿	流通市值14.85亿	总股本1.18亿
成交额4,020万	换手率2.68%	流通股本1.12亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTLA","market":"US","secType":"STK","nameCN":"Intellia Therapeutics Inc","latestPrice":13.26,"timestamp":1774468800000,"preClose":12.81,"halted":0,"volume":3005545,"hourTrading":{"tag":"盘后","latestPrice":13.37,"preClose":13.26,"latestTime":"17:48 EDT","volume":30185,"amount":397050.04891,"timestamp":1774475293096,"change":0.11,"changeRate":0.008296,"amplitude":0.024133},"delay":0,"changeRate":0.03512880562060884,"floatShares":112000000,"shares":118133546,"eps":-3.81,"marketStatus":"盘后交易","change":0.45,"latestTime":"03-25 18:01:29 EDT","open":13.11,"high":13.67,"low":13.0323,"amount":40199257.546895,"amplitude":0.049781,"askPrice":13.37,"askSize":200,"bidPrice":13.12,"bidSize":1430,"shortable":3,"etf":0,"ttmEps":-3.81,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774483200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1462507200000,"exchange":"NASDAQ","adjPreClose":12.81,"preHourTrading":{"tag":"盘前","latestPrice":13,"preClose":12.81,"latestTime":"09:27 EDT","volume":1882,"amount":24317.704046,"timestamp":1774445260055,"change":0.19,"changeRate":0.014832,"amplitude":0.022639},"postHourTrading":{"tag":"盘后","latestPrice":13.37,"preClose":13.26,"latestTime":"17:48 EDT","volume":30185,"amount":397050.04891,"timestamp":1774475293096,"change":0.11,"changeRate":0.008296,"amplitude":0.024133},"volumeRatio":0.868554,"impliedVol":0.896,"impliedVolPercentile":0.4223},"requestUrl":"/m/hq/s/NTLA","defaultTab":"news","newsList":[{"id":"1167845136","title":"异动解读 | FDA解除心脏病基因疗法临床搁置，Intellia Therapeutics盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167845136","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167845136?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:51","pubTimestamp":1772466703,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc  今日盘中股价大幅上涨5.01%，引起了市场的广泛关注。消息面上，美国食品药品监督管理局已解除对其治疗心脏病的实验性基因疗法后期临床试验的临床搁置。据悉，该基因编辑疗法名为nexiguran ziclumeran，旨在治疗转甲状腺素蛋白淀粉样变性心肌病。去年，因一名患者出现严重的肝脏并发症，FDA暂停了相关试验。今年1月，FDA解除了对其中一项试验的搁置，而本次解除搁置涉及第二项试验，意味着该疗法的心脏病临床试验得以全面恢复。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"gpt_icon":0},{"id":"1168319211","title":"FDA解除临床暂停后，Intellia Therapeutics盘前股价大涨7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168319211","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168319211?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:45","pubTimestamp":1772455511,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）解除了对Intellia Therapeutics公司心脏病基因疗法试验的临床暂停后，该公司股价在盘前交易中上涨7%。这一监管进展为基因疗法领域注入了新的乐观情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861559042.SGD","BK4556","NTLA","BK4535","BK4588","BK4585","LU1861558580.USD"],"gpt_icon":0},{"id":"1188869451","title":"异动解读 | FDA解除临床试验暂停令，Intellia Therapeutics盘前大涨7.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188869451","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188869451?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:34","pubTimestamp":1772454883,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc (NTLA)今日盘前股价大幅上涨7.40%，引起了市场的广泛关注。消息面上，Intellia Therapeutics宣布，美国食品药品监督管理局（FDA）已解除对其针对转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）的Magnitude三期临床试验的临床暂停令，这一决定意味着该重要临床研究项目将得以重新启动并继续推进。对于生物技术公司而言，关键临床试验的进展是影响其估值的重要因素，FDA解除暂停令被视为积极的监管进展，增强了市场对该药物研发前景的信心，从而推动了股价的显著上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"gpt_icon":0},{"id":"1140409010","title":"Intellia Therapeutics宣布美国FDA解除针对ATTR-CM适应症的Magnitude三期临床试验暂停","url":"https://stock-news.laohu8.com/highlight/detail?id=1140409010","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140409010?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:32","pubTimestamp":1772454759,"startTime":"0","endTime":"0","summary":"生物技术公司Intellia Therapeutics宣布，美国食品药品监督管理局（FDA）已解除对其针对转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）的Magnitude三期临床试验的临床暂停令。这一决定意味着该重要临床研究项目将得以重新启动并继续推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","BK4535","LU1861559042.SGD","LU1861558580.USD","BK4556","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"1160163450","title":"异动解读 | 财报显示净亏损近亿美元，Intellia Therapeutics盘后大跌5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160163450","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160163450?lang=zh_cn&edition=full","pubTime":"2026-02-27 06:13","pubTimestamp":1772144017,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) 今日盘后股价大跌5.46%，引起了市场的关注。消息面上，公司最新发布的第四季度财报显示，净亏损达到9578.6万美元，运营支出高达1.217亿美元。这一财务表现凸显了公司在研发领域的持续高投入，但同时也给投资者带来了对盈利能力的担忧，可能导致了股价的下跌。Intellia Therapeutics是一家专注于基因编辑疗法的生物技术公司，尽管财务表现承压，公司仍致力于前沿技术的探索，但短期内的亏损可能影响了市场情绪。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"gpt_icon":0},{"id":"1155372170","title":"Intellia Therapeutics第四季度净亏损达9578.6万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155372170","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155372170?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:51","pubTimestamp":1772110277,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics最新财报显示，公司第四季度运营支出高达1.217亿美元。这一数据凸显了这家生物技术公司在研发领域的持续投入。尽管财务表现承压，但公司仍专注于基因编辑疗法的前沿探索。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NTLA","LU1861558580.USD","BK4588","BK4585","LU1861559042.SGD","BK4535","BK4556"],"gpt_icon":0},{"id":"2614110703","title":"Intellia Therapeutics, Inc.盘中异动 下午盘股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614110703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614110703?lang=zh_cn&edition=full","pubTime":"2026-02-25 03:00","pubTimestamp":1771959644,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日03时00分，Intellia Therapeutics, Inc.股票出现异动，股价大幅上涨5.02%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，专注于开发基于Crispr/ cas9的治疗方法。Intellia专注于利用这项技术治疗基因定义的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602250300459541d903&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602250300459541d903&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LU1861559042.SGD","BK4585","BK4588","BK4539","BK4556","NTLA","LU1861558580.USD","BK4007","BK4139","BK4535"],"gpt_icon":0},{"id":"1108507470","title":"Intellia Therapeutics股价盘前飙升23.7% 美国FDA解除其基因疗法临床试验暂停","url":"https://stock-news.laohu8.com/highlight/detail?id=1108507470","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108507470?lang=zh_cn&edition=full","pubTime":"2026-01-27 21:55","pubTimestamp":1769522112,"startTime":"0","endTime":"0","summary":"基因编辑公司Intellia Therapeutics Inc（NTLA）股价在周一盘前交易中大幅上涨23.7%，此前美国食品药品监督管理局（FDA）解除了对其一项在研基因疗法临床试验的暂停令。这一监管进展为该公司重启相关临床研究扫清了障碍，显著提振了市场信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4588","BK4585","BK4139","LU1861558580.USD","NTLA","BK4535","BK4556"],"gpt_icon":0},{"id":"1116166629","title":"Intellia Therapeutics第三季度净收入为-1.01324亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116166629","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116166629?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:59","pubTimestamp":1763571587,"startTime":"0","endTime":"0","summary":"11月6日——Intellia Therapeutics第三季度营业收入为-1.11477亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4556","BK4139","LU1861559042.SGD","BK4585","LU1861558580.USD","BK4588","NTLA"],"gpt_icon":0},{"id":"2582308381","title":"华尔街顶级分析师最新评级报告：美国电话电报公司评级上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2582308381","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582308381?lang=zh_cn&edition=full","pubTime":"2025-11-12 23:05","pubTimestamp":1762959900,"startTime":"0","endTime":"0","summary":"华尔街最受关注、且能影响市场走势的研究评级报告现已汇总一处。KeyBanc 银行将美国电话电报公司的评级从 “行业权重” 上调至 “增持”，目标股价定为 30 美元。伯恩斯坦公司首次覆盖辛塔斯公司，给予 “与大盘持平” 评级，目标股价定为 200 美元。该机构认为，辛塔斯是一家 “优质成长型公司”，但当前股价已处于高位。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-11-12/doc-infxemns6034755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CTAS","BK4588","GRAL","LU0175139822.USD","OUT","KMX","BK4141","BK4534","LU1621767810.EUR","T","BK4507","BK4550","BK4234","BK4154","NUVL","BK4585","IE00BSNM7G36.USD","QUIK","BK4535","BK4214","ATAT","BK4598","BK4215","LU0650527681.SGD","BK4139","BBWI","LU1571399168.USD","LU1621768206.USD","LU1169589451.USD","LU1621768115.EUR","CSR","LU2506951958.HKD","BK4548","AN","LU0823417653.USD","CVNA","BK4137","BK4142","BK4503","BK4556","LU1861558580.USD","LU1169590202.USD","PGNY","BK4200","NTLA","BK4162","LU0211326839.USD","LU2506952170.USD","BHF","FND"],"gpt_icon":0},{"id":"2580210732","title":"Intellia Therapeutics, Inc.盘中异动 早盘股价大涨5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580210732","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580210732?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:30","pubTimestamp":1762180243,"startTime":"0","endTime":"0","summary":"北京时间2025年11月03日22时30分，Intellia Therapeutics, Inc.股票出现波动，股价快速上涨5.65%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110322304394ec544d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110322304394ec544d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU1861559042.SGD","LU1861558580.USD","LENZ","BK4535","NTLA","BK4007","BK4556","BK4585","BK4539","BK4139"],"gpt_icon":1},{"id":"1121677033","title":"Intellia Therapeutics Inc - FDA对Nex-Z的Magnitude和Magnitude-2试验实施临床暂停 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1121677033","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121677033?lang=zh_cn&edition=full","pubTime":"2025-10-30 05:00","pubTimestamp":1761771612,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc - FDA对Nex-Z的Magnitude和Magnitude-2试验实施临床暂停 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1861559042.SGD","BK4535","BK4139","BK4556","LU1861558580.USD","BK4588","NTLA"],"gpt_icon":0},{"id":"1128309851","title":"Intellia Therapeutics Inc : 富国银行将评级下调至持平，目标价降至17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1128309851","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128309851?lang=zh_cn&edition=full","pubTime":"2025-10-28 18:57","pubTimestamp":1761649033,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc : 富国银行将评级下调至持平，目标价从45美元降至17美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","BK4585","BK4556","BK4535","BK4588","LU1861559042.SGD","LU1861558580.USD","BK4139"],"gpt_icon":0},{"id":"1126561246","title":"Intellia Therapeutics Inc: Bernstein将评级下调至市场表现，从跑赢大盘调整为市场表现；目标价上调至14.5美元，从14美元上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1126561246","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126561246?lang=zh_cn&edition=full","pubTime":"2025-10-28 18:49","pubTimestamp":1761648549,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc: Bernstein将评级下调至市场表现，从跑赢大盘调整为市场表现；目标价上调至14.5美元，从14美元上调。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4588","NTLA","BK4139","BK4585","LU1861559042.SGD","BK4556","LU1861558580.USD"],"gpt_icon":0},{"id":"2578056446","title":"nex-z三期临床试验出现严重不良事件，Intellia股价暴跌超40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578056446","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578056446?lang=zh_cn&edition=full","pubTime":"2025-10-28 08:25","pubTimestamp":1761611140,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，$Intellia$ $Therapeutics$公司在暂停两项nexiguran ziclumeran三期临床试验的给药后，其股价于周一交易中一度暴跌47.6%，收跌42.23%。此次暂停给药，源于MAGNITUDE试验中出现一例严重不良事件报告：一名患者因出现4级肝转氨酶升高及总胆红素升高而住院。另一项暂停的试验为MAGNITUDE-2，其研究方向是转甲状腺素蛋白淀粉样变性多发性神经病。截至当前，MAGNITUDE试验已入组650名患者，MAGNITUDE-2试验已入组47名患者。据估算，已有超过450名患者接受过nex-z给药治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"nex-z三期临床试验出现严重不良事件，Intellia股价暴跌超40%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU1861559042.SGD","BK4535","BK4139","BK4556","LU1861558580.USD","BK4588","NTLA"],"gpt_icon":0},{"id":"2578236196","title":"美股异动 | 暂停nex-z三期临床试验的患者给药和筛查工作 Intellia Therapeutics(NTLA.US)暴跌超45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578236196","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578236196?lang=zh_cn&edition=full","pubTime":"2025-10-27 23:21","pubTimestamp":1761578469,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，Intellia Therapeutics(NTLA.US)暴跌超45%，报13.90美元。消息面上，Intellia Therapeutics表示，已暂停其两项关于nex-z的三期临床试验的患者给药和筛查工作。这些试验分别针对患有转甲状腺素蛋白淀粉样变性伴心肌病和多发性神经病的患者，原因是一名患者在用药后报告出现4级肝转氨酶升高以及总胆红素增加的情况。该患者已住院并正在接受医疗干预。Intellia称正在咨询专家，并正在考虑潜在的风险缓解策略，同时也在与监管机构沟通，目标是在适当时尽快恢复试验招募。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4539","BK4556","NTLA","LENZ","LU1861559042.SGD","BK4535","BK4588","BK4007","BK4139","BK4585","LU1861558580.USD"],"gpt_icon":0},{"id":"1189900761","title":"盘前异动 | 基因编辑公司NTLA一度暴跌超60%，引发相关概念股集体下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1189900761","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189900761?lang=zh_cn&edition=full","pubTime":"2025-10-27 20:20","pubTimestamp":1761567653,"startTime":"0","endTime":"0","summary":"10月27日，基因编辑公司$Intellia $Therapeutics(LENZ)$(NTLA)$盘前一度暴跌超60%，消息面上，该公司宣布暂停其针对转甲状腺素蛋白淀粉样伴心肌病（ATTR-CM）和多神经病（ATTR-PN）患者的给药和筛查程序。受上述消息影响，美股基因编辑概念股盘前集体下挫，$Beam Therapeutics(BEAM)$跌超10%，$Editas Medicine(EDIT)$跌超8%，$CRISPR Therapeutics(CRSP)$跌超5%。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"16e1b265add1344611becaeeb33ca152","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","NTLA"],"gpt_icon":0},{"id":"1104359214","title":"Intellia Therapeutics因肝脏问题暂停实验性基因编辑疗法的后期试验，股价盘前下跌46%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104359214","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104359214?lang=zh_cn&edition=full","pubTime":"2025-10-27 20:07","pubTimestamp":1761566821,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics因暂停实验性基因编辑疗法的后期试验，导致股价在盘前交易中下跌46%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"16e1b265add1344611becaeeb33ca152","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861559042.SGD","BK4556","NTLA","BK4535","BK4588","BK4585","LU1861558580.USD"],"gpt_icon":0},{"id":"2575700102","title":"Intellia Therapeutics, Inc.盘中异动 早盘大幅下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575700102","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575700102?lang=zh_cn&edition=full","pubTime":"2025-10-14 21:35","pubTimestamp":1760448920,"startTime":"0","endTime":"0","summary":"北京时间2025年10月14日21时35分，Intellia Therapeutics, Inc.股票出现波动，股价快速跳水5.01%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.40%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014213520a6b915f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014213520a6b915f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU1861559042.SGD","LU1861558580.USD","NTLA","BK4588","BK4585","BK4535","BK4556","BK4139","BK4539","LENZ"],"gpt_icon":1},{"id":"1110009978","title":"Intellia Therapeutics Inc公司单剂Nex-Z显示TTR蛋白持续降低至少90%，效果维持三年","url":"https://stock-news.laohu8.com/highlight/detail?id=1110009978","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110009978?lang=zh_cn&edition=full","pubTime":"2025-09-25 21:53","pubTimestamp":1758808403,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc公司单剂Nex-Z显示TTR蛋白持续降低至少90%，效果维持三年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4556","BK4535","BK4588","BK4139","BK4585","LU1861559042.SGD","NTLA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intelliatx.com","stockEarnings":[{"period":"1week","weight":-0.0497},{"period":"1month","weight":0.0134},{"period":"3month","weight":0.3358},{"period":"6month","weight":-0.2288},{"period":"1year","weight":0.3759},{"period":"ytd","weight":0.4249}],"compareEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.0074},{"period":"1year","weight":0.1378},{"period":"ytd","weight":-0.0421}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司，专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用，发展有潜能的新一代治疗产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.046678},{"month":2,"riseRate":0.7,"avgChangeRate":0.065016},{"month":3,"riseRate":0.2,"avgChangeRate":-0.068657},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.038358},{"month":5,"riseRate":0.222222,"avgChangeRate":0.002269},{"month":6,"riseRate":0.9,"avgChangeRate":0.229655},{"month":7,"riseRate":0.6,"avgChangeRate":0.044195},{"month":8,"riseRate":0.5,"avgChangeRate":0.02106},{"month":9,"riseRate":0.2,"avgChangeRate":-0.010821},{"month":10,"riseRate":0.2,"avgChangeRate":-0.105594},{"month":11,"riseRate":0.6,"avgChangeRate":0.07833},{"month":12,"riseRate":0.3,"avgChangeRate":-0.083863}],"exchange":"NASDAQ","name":"Intellia Therapeutics Inc","nameEN":"Intellia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intellia Therapeutics Inc,NTLA,Intellia Therapeutics Inc股票,Intellia Therapeutics Inc股票老虎,Intellia Therapeutics Inc股票老虎国际,Intellia Therapeutics Inc行情,Intellia Therapeutics Inc股票行情,Intellia Therapeutics Inc股价,Intellia Therapeutics Inc股市,Intellia Therapeutics Inc股票价格,Intellia Therapeutics Inc股票交易,Intellia Therapeutics Inc股票购买,Intellia Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}